In this AJMC® roundtable discussion, oncology health care decision-making experts consider factors that affect the use of cancer immunotherapies (CITs) and discuss approaches for actualizing policies and procedures within community oncology teams.
Evaluating the Management of Cancer Immunotherapy (CIT): Roundtable Discussion
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Semaglutide Label to Reduce Cardiovascular Risk in Adults With Type 2 Diabetes
2
Shifts in Colorectal Cancer Screening Trends After COVID-19
3
Challenges, Opportunities in Implementing the MDPP: Melanie T. Turk, PhD, RN
4
3 New Study Findings to Look Out for at Menopause Society 2025
5
